Medical expert video library
Hear from oncologists and medical experts about KISQALI® (ribociclib) in stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence.
The health care providers and patients in the videos below have been compensated for their time by Novartis Pharmaceuticals Corporation.
MORE PERSPECTIVES
Ursa Brown-Glaberman, MD, shares her approach for talking with patients about risk of recurrence
How does Dr Brown-Glaberman discuss risk of recurrence with her patients who have stage II/III HR+/HER2- eBC? Watch to get her perspective on talking early and often with patients about their risk and appropriate treatment plan.
Learn more: Explore risk of recurrence data in HR+/HER2- eBC
eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive.
Michelina Cairo, MD, discusses her process for choosing an adjuvant treatment
How does Dr Cairo decide which adjuvant treatment is right for her patients with stage II/III HR+/HER2- eBC? Watch to learn how she evaluates each of the patients in her practice to choose which adjuvant treatment is appropriate for them.
Learn more: Explore patient eligibility for KISQALI in HR+/HER2- eBC
CDK, cyclin-dependent kinase.
RISK OF RECURRENCE
Risk of recurrence in HR+/HER2- eBC and the NATALEE trial design
Risk of recurrence in HR+/HER2- eBC and the NATALEE trial design
Which patients are at risk of recurrence? Four expert medical oncologists discuss unmet medical needs in the eBC landscape, including risk of recurrence, and review the study design and patient population included in the pivotal phase III NATALEE trial.
Learn more: Explore risk of recurrence data in HR+/HER2- eBC
PATIENT MANAGEMENT
Patient management and support with KISQALI in eBC
Patient management and support with KISQALI in eBC
Are support resources available for KISQALI? Hear perspectives from an expert panel of medical oncologists on how to optimize patient management and access support resources for patients treated with KISQALI in the adjuvant setting.